AngioDynamics, Inc. , a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations ...

The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's highly-effective Zepbound, but Amgen is taking a ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

BeiGene's BTK inhibitor Brukinsa (zanubrutinib ... 10 months after Brukinsa was approved by the Medicines and Healthcare products Regulatory Agency (MHRA). That approval also included first ...

🗣 I've taught over 100,000 students on products such as HashiCorp Terraform, Vault, Consul, Packer, Nomad, AWS services, and GitHub, among others. 🚀 I also specialize in AWS, with over 10 years ...

Learn more about whether Avidity Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration ... Bruton's tyrosine kinase (BTK) inhibitor in adult patients with chronic lymphocytic leukemia ...

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS MASITINIB PLATFORMParis, January 29, 2025, 7pm CETAB Science SA (Euronext - FR0010557264 - AB) ...